Peptides represent software for human biology
The guest argued that peptides act as biological software, marking a structural market rotation from tech hardware to biotech application layers.
The argument
The guest highlighted Eli Lilly's massive addressable market and its strategic partnership with NVIDIA to use AI to accelerate drug discovery. Furthermore, the therapeutic benefits of GLP-1s are expanding beyond weight loss into addiction and metabolic diseases, creating significant second-order economic impacts across consumer sectors.
The thesis, stress-tested
✓ What validates it
- ✓Eli Lilly announcing successful clinical trials for addiction or other non-obesity indications
- ✓Additional consumer discretionary companies reporting earnings growth attributed to GLP-1 adoption
- ✓Eli Lilly acquiring more metabolic disease-focused biotech companies
▸ Risks discussed
- ▸High cost of treatments limiting patient access
- ▸Lack of insurance coverage for weight-loss indications
- ▸Competitors using AI to rapidly replicate proprietary IP
Hear it yourself
"with Eli Lilly, why he is so convicted that it could be the best AI name for the AI trade. And then we get into a bunch of other second and third order effects of what's going on with the infrastructure build out, artificial intelligence, so much tokens being consumed. And then how does Bitcoin fit into all this? All that much more in this conversation with Jordy Visser. Alright, Jordy. Bitcoin is down 50% from its all time high. People are freaking out. Michael Saylor sold 32 Bitcoin this week, and people think that maybe he doesn't believe anymore."
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE